Top

Published in:

01-04-2010

Uric Acid as a Factor in the Metabolic Syndrome

Authors: Rodolfo Leão Borges, Artur Beltrame Ribeiro, Maria Teresa Zanella, Marcelo Costa Batista

Published in: Current Hypertension Reports | Issue 2/2010

Abstract

Hyperuricemia is a prevalent finding in patients presenting metabolic syndrome, although its clinical meaning is still controversial and often underestimated. Men and women have different serum urate levels at all ages, and the impact of hyperuricemia in cardiovascular and renal outcomes is generally associated with a worse prognosis in women. Recent studies also have called attention to another perspective on hyperuricemia, indicating that it may be not only a consequence of insulin resistance states but also a significant predictor of the development of metabolic syndrome. This review discusses recent evidence related to the clinical significance of hyperuricemia in both sexes and the potential benefits of lowering serum uric acid levels.

Wilson PW, D’Agostino RB, Parise H, et al.: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066–3072.CrossRefPubMed

Rathmann W, Funkhouser E, Dyer AR, et al.: Relation of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998, 8:250–261.CrossRefPubMed

Facchini F, Chen Y-DI, Hollenbeck CB, et al.: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid and clearance, and plasma uric acid concentration. JAMA 1992, 206:3008–3011.

Iwatani M, Wasada T, Katsumori K, et al.: Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics. Diabetologia 2000, 43: 814–815.CrossRefPubMed

Matsuura F, Yamashita S, Nakamura T, et al.: Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998, 47: 929–933.CrossRefPubMed

Culleton BF, Larson MG, Kannel WB, et al.: Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999, 131:7–13.PubMed

Nicholls A, Snaith ML, Scott JT: Effect of oestrogen therapy on plasma and urinary levels of uric acid. BMJ 1973, 1:449–451.CrossRefPubMed

Yahyaoui R, Esteva I, Haro-Mora JJ, et al.: Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons. J Clin Endocrinol Metab 2008, 93(6):2230–2233.CrossRefPubMed

Hosoyamada M, Ichida K, Enomoto A, et al.: Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol 2004, 15:261–268.CrossRefPubMed

10.

Nakagawa T, Kang D-H, Feig D, et al.: Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int 2006, 69(10):1722–1725.CrossRefPubMed

11.

Mazzali M, Hughes J, Kim YG, et al.: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001, 38:1101–1106.CrossRefPubMed

12.

Corry DB, Eslami P, Yamamoto K, et al.: Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008, 26:269–275.CrossRefPubMed

13.

Mazzali M, Kanellis J, Han L, et al.: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282:F991–F997.PubMed

14.

Tuttle KR, Short RA, Johnson RJ: Sex differences in uric acid and in risk factors for coronary artery disease. Am J Cardiol 2001, 87:1411–1414.CrossRefPubMed

15.

Freedman DS, Williamson DF, Gunter EW, et al.: Relation of serum uric acid to mortality and Ischemic heart disease. The NHANES I Epidemiologic Follow-up study. Am J Epidemiol 1995,141:637–644.PubMed

16.

Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000, 283(18):2404–2410.

17.

Persky VW, Dyer AR, Idris-Soven E, et al.: Uric acid: a risk factor for coronary heart disease? Circulation 1979, 59(5):969–977.PubMed

18.

Høieggen A, Alderman MH, Kjeldsen SE, et al.: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004, 65(3):1041–1049.CrossRefPubMed

19.

Alper AB Jr, Chen W, Yau L, et al.: Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension 2005, 45:34–38.PubMed

20.

Krishnan E, Kwoh CK, Schumacher HR, Kuller L: Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007, 49:298–303.CrossRefPubMed

21.

Feig DI, Soletsky B, Johnson RJ: Effect of allopurinol on the blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2008, 300:924–932.CrossRefPubMed

22.

Kannel WB: Incidence and epidemiology of heart failure. Heart Fail Rev 2000, 5:167–173.CrossRefPubMed

23.

Liao Y, Cooper RS, Mensah GA, et al.: Left ventricular hypertrophy has a greater impact on survival in women than in men. Circulation 1995, 92:805–810.PubMed

24.

Viazzi F, Parodi D, Leoncini G, et al.: Serum uric acid and target organ damage in primary hypertension. Hypertension 2005, 45:991–996.CrossRefPubMed

25.

Sui X, Church TS, Meriwether RA, et al.: Uric acid and the development of metabolic syndrome in women and men. Metabolism 2008, 57:845–852.CrossRefPubMed

26.

Dehghan A, van Hoek M, Sijbrands EJ, et al.: High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008, 31:361–362.CrossRefPubMed

27.

See LC, Kuo CF, Chuang FH, et al.: Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol 2009, 36(8):1691–1698.CrossRefPubMed

28.

Nakagawa T, Hu H, Zharikov S, et al.: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006, 290(3):F625–F631.CrossRefPubMed

29.

Mu W, Krotova K, Block ER, et al.: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67:1739–1742.CrossRefPubMed

30.

•• Johnson RJ, Perez-Pozo SE, Sautin YY, et al.: Hypothesis: Could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 2009 ,30(1):96–116. This detailed review includes all recent findings connecting hyperuricemia to the development of metabolic syndrome.

31.

Sautin YY, Nakagawa T, Zharikov S, et al.: Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007, 293:C584–C596.CrossRefPubMed

32.

Furukawa S, Fujita T, Shimabukuro M, et al.: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752–1761.PubMed

33.

Barrett-Connor E, Ferrara A: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998, 21:1236–1239.CrossRef

34.

Lundberg V, Stegmayr B, Asplund K, et al.: Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med 1997, 241:485–492.PubMed

35.

Scheidt-Nave C, Barrett-Connor E, Wingard DL, et al.: Sex differences in fasting glycemia as a risk factor for ischemic heart disease death. Am J Epidemiol 1991, 133:565–576.PubMed

36.

Huxley R, Barzi F, Woodward M: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332(7533):73–78.CrossRefPubMed

37.

Cannon PJ, Stason WB, Demartini FE, et al.: Hyperuricemia in primary and renal hypertension. N Engl J Med 1966, 275:457–464.PubMedCrossRef

38.

Messerli FH, Frohlich ED, Dreslinski GR, et al.: Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980, 93:817–821.PubMed

39.

Barlow K, Beilin L: Renal disease in primary gout. Q J Med 1968, 37:79–98.PubMed

40.

Sanchez-Lozada LG, Tapia E, Soto V, et al.: Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 2008, 108:69–78.CrossRef

41.

Iseki K, Ikemiya Y, Inoue T, et al.: Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004, 44(4):642–650.CrossRefPubMed

42.

Obermayr RP, Temml C, Gutjahr G, et al.: Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008, 19(12):2407–2413.CrossRefPubMed

43.

Syrjänen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000, 15(1):34–42.CrossRefPubMed

44.

• Hsu CY, Iribarren C, McCulloch CE, et al.: Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009, 169(4):342–350. This important study with a large cohort demonstrates an independent role for UA as a predictor of renal dysfunction.

45.

Borges RL, Hirota AH, Quinto BM, et al.: Uric acid as a marker for renal dysfunction in hypertensive women on diuretic and nondiuretic therapy. J Clin Hypertens 2009, 11:253–259.CrossRef

46.

Iseki K, Oshiro S, Tozawa M, et al.: Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 2001, 24:691–697.CrossRefPubMed

47.

Lee JE, Kim YG, Choi YH, et al.: Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006, 47:962–967.CrossRefPubMed

48.

Chonchol M, Shlipak MG, Katz R, et al.: Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007, 50(2):239–247.CrossRefPubMed

49.

Madero M, Sarnak MJ, Wang X, et al.: Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009, 53(5):796–803.CrossRefPubMed

50.

Athyros VG, Elisaf M, Papageorgiou AA, et al.: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004, 43(4):589–599.CrossRefPubMed

51.

Luk AJ, Levin GP, Moore EE, et al.: Allopurinol and mortality in hyperuricaemic patients. Rheumatology 2009, 48(7):804–806.CrossRefPubMed

52.

Siu YP, Leung KT, Tong MK, et al.: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006, 47(1):51–59.CrossRefPubMed

53.

Kanbay M, Ozkara A, Selcoki Y, et al.: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007, 39(4):1227–1233.CrossRefPubMed

54.

Talaat KM, el-Sheikh AR: The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007, 27(5):435–440.CrossRefPubMed

Title: Uric Acid as a Factor in the Metabolic Syndrome
Authors: Rodolfo Leão Borges
Artur Beltrame Ribeiro
Maria Teresa Zanella
Marcelo Costa Batista
Publication date: 01-04-2010
Publisher: Current Science Inc.
Published in: Current Hypertension Reports / Issue 2/2010
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-010-0098-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Uric Acid as a Factor in the Metabolic Syndrome

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Carotid Baroreflex Activation: Past, Present, and Future

INVESTing in Hypertension

Oxidative Stress and Hypertension: Current Concepts

Modulation of Pressure-Natriuresis by Renal Medullary Reactive Oxygen Species and Nitric Oxide

The Evolution of Renin-Angiotensin Blockade: Angiotensin-Converting Enzyme Inhibitors as the Starting Point

Central Adiposity, Systemic Inflammation, and the Metabolic Syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page